NCT05004688View on ClinicalTrials.gov

A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 25, 2022

Primary Completion Date

January 15, 2024

Study Completion Date

January 15, 2024

Conditions
Mild Cognitive ImpairmentMild DementiaModerate DementiaAlzheimer Disease
Interventions
BIOLOGICAL

Biological/Vaccine: Bacillus Calmette-Guerin (BCG)

Two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 0.36-3.9 x 10\^6 colony forming units (CFU) reconstituted in 0.1 mL saline.

Trial Locations (1)

02129

Alzheimer's Clinical and Translational Research Unit, Charlestown

All Listed Sponsors
lead

Steven E Arnold, MD

OTHER